Trevi Therapeutics (TRVI) Other Working Capital Changes (2018 - 2025)
Trevi Therapeutics' quarterly Other Working Capital Changes came in at -$158000.0 in Q4 2025, down 305.19% year-on-year from $77000.0 in Q4 2024, and down 1240.46% quarter-over-quarter from $13854.0 in Q2 2025.
Trevi Therapeutics has reported Other Working Capital Changes for 8 years, with the latest figure at -$158000.0 in Q4 2025.
- For the quarter ending Q4 2025, Other Working Capital Changes fell 305.19% year-over-year to -$158000.0; the trailing twelve-month figure through Dec 2025 stood at -$60000.0 (up 89.47% YoY), and the FY2024 full-year result was $67828.0, down 71.42% from the prior year.
- Other Working Capital Changes for Q4 2025 stood at -$158000.0, down from $13854.0 in the prior quarter.
- The five-year high for Other Working Capital Changes was $605000.0 in Q1 2025, with the low at -$584000.0 in Q1 2024.
- Average Other Working Capital Changes over 5 years is -$10132.2, with a median of $13854.0 recorded in 2025.
- Year-over-year, Other Working Capital Changes sank 36590.01% in 2022 and soared 7795.48% in 2023.
- Tracing TRVI's Other Working Capital Changes over 5 years: stood at -$464000.0 in 2021, then surged by 104.74% to $22000.0 in 2022, then sank by 486.36% to -$85000.0 in 2023, then surged by 190.59% to $77000.0 in 2024, then sank by 305.19% to -$158000.0 in 2025.
- The last three Other Working Capital Changes figures came in at -$158000.0 (Q4 2025), $13854.0 (Q2 2025), and $605000.0 (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -158,000.00 |
| Dec 31, 2025 | -158,000.00 |
| Jun 30, 2025 | 13,854.00 |
| Jun 30, 2025 | 13,854.00 |
| Mar 31, 2025 | 605,000.00 |
| Mar 31, 2025 | 605,000.00 |
| Dec 31, 2024 | 77,000.00 |
| Dec 31, 2024 | 77,000.00 |
| Sep 30, 2024 | 67,828.00 |
| Sep 30, 2024 | 67,828.00 |
| Jun 30, 2024 | 67,828.00 |
| Jun 30, 2024 | 67,828.00 |
| Mar 31, 2024 | -584,000.00 |
| Mar 31, 2024 | -584,000.00 |
| Dec 31, 2023 | -85,000.00 |
| Dec 31, 2023 | -85,000.00 |
| Sep 30, 2023 | 234,876.00 |
| Sep 30, 2023 | 234,876.00 |
| Jun 30, 2023 | 207,730.00 |
| Jun 30, 2023 | 207,730.00 |
| Mar 31, 2023 | 4,211.00 |
| Mar 31, 2023 | 4,211.00 |
| Dec 31, 2022 | 22,000.00 |
| Dec 31, 2022 | 22,000.00 |
| Sep 30, 2022 | 36,297.00 |
| Sep 30, 2022 | 36,297.00 |
| Jun 30, 2022 | 2,631.00 |
| Jun 30, 2022 | 2,631.00 |
| Mar 31, 2022 | -420,000.00 |
| Mar 31, 2022 | -420,000.00 |
| Dec 31, 2021 | -464,000.00 |
| Dec 31, 2021 | -464,000.00 |
| Sep 30, 2021 | 176,931.00 |
| Sep 30, 2021 | 176,931.00 |
| Jun 30, 2021 | 1,151.00 |
| Jun 30, 2021 | 1,151.00 |
| Mar 31, 2021 | 1,151.00 |
| Mar 31, 2021 | 1,151.00 |
| Dec 31, 2020 | -419,000.00 |
| Dec 31, 2020 | -419,000.00 |
| Sep 30, 2020 | 11,842.00 |
| Sep 30, 2020 | 11,842.00 |
| Jun 30, 2020 | 983,000.00 |
| Jun 30, 2020 | 983,000.00 |
| Mar 31, 2020 | -1.06 Mn |
| Mar 31, 2020 | -1.06 Mn |
| Dec 31, 2019 | -145,000.00 |
| Dec 31, 2019 | -145,000.00 |
| Sep 30, 2019 | 6,359.00 |
| Sep 30, 2019 | 6,359.00 |
| Jun 30, 2019 | 5,592.00 |
| Jun 30, 2019 | 5,592.00 |
| Mar 31, 2019 | 230,000.00 |
| Mar 31, 2019 | 230,000.00 |
| Dec 31, 2018 | -155,000.00 |
| Dec 31, 2018 | -155,000.00 |
| Mar 31, 2018 | 176,000.00 |
| Mar 31, 2018 | 176,000.00 |